Summary
The pharmacokinetics and metabolism of cyclophosphamide were studied in nine paediatric patients. Plasma samples were obtained from eight subjects and urine was collected from six children during a 24-h period after drug administration. Cyclophosphamide and its major metabolites phosphoramide mustard (PM), carboxyphosphamide (CX), dechloroethylcyclophosphamide (DCCP) and 4-ketocyclophosphamide (KETO) were determined in plasma and urine using high-performance thin-layer chromatography-photographic densitometry (HPTLC-PD). Cyclophosphamide (CP) was nearly, if not completely, cleared from plasma by 24 h after its administration. The plasma half-life of CP ranged from 2.15 to 8.15 h; it decreased following higher doses and was shorter than that previously reported for adult patients. Both the apparent volume of distribution (0.49±1.4 l/kg) and the total body clearance (2.14±1.4 l m−2 h−1) increased with increasing dose. Renal clearance ranged between 0.12 and 0.58 l/h (mean, 0.43±0.19l/h). Between 5.4% and 86.1% of the total delivered dose was recovered as unchanged drug in the urine. The major metabolites identified in plasma and urine were PM and CX. One patient appeared to be deficient in CX formation. This study suggests that there is interpatient variability in the pharmacokinetics and metabolism of CP in paediatric patients. The shorter half-life and higher clearance as compared with adult values indicate faster CP metabolism in children.
Similar content being viewed by others
References
Balis FM, Holcenberg JS, Poplack DG (1988) General principles of chemotherapy. In: Pizzo PA, Poplack DG (eds) Principles and practice of pediatric oncology. J. B. Lippincott, Philadelphia, p 165
Clarke L, Waxman DJ (1989) Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res 49: 2344
Edwards G, Calvert RT, Crowther D, Bramwell V, Scarffe H (1980) Repeated investigations of cyclophosphamide disposition in myeloma patients receiving intermittent chemotherapy. Br J Clin Pharmacol 10: 281
Erlichman C, Soldin SJ, Hardy RW, Thiessen RW, Sturgeon JFG, Fine S, Baskerville T (1988) Disposition of cyclophosphamide on two consecutive cycles of treatment in patients with ovarian carcinoma. Drug Res 38: 839
Faber OK, Mourisden HT, Skovsted L (1974) The biotransformation of cyclophosphamide in man: influence of prednisone. Acta Pharmacol Toxicol 35: 195
Gershwin ME, Goetzl EJ, Steinberg AD (1974) Cyclophosphamide: use in practice. Ann Intern Med 80: 531
Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York
Graham MI, Shaw IC, Souhami RL, Sidau B, Harper PG, McLean AEM (1983) Decreased plasma half-life of cyclophosphamide during repeated high-dose administration. Cancer Chemother Pharmacol 15: 192
Hadidi AFA, Coulter CEA, Idle JR (1988) Phenotypically deficient climination of carboxyphosphamide after cyclophosphamide administration to cancer patients. Cancer Res 48: 5167
Hadidi AFA, Idle JR (1988) Combined thin-layer chromatographyphotography-densitometry for the quantitation of cyclophosphamide and its four principal urinary metabolites. J Chromatogr 427: 121
Juma FD, Rogers HJ, Trounce JR (1979) Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. Br J Clin Pharmacol 8: 209
Juma FD, Rogers HJ, Trounce JR (1980) The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy. Br J Clin Pharmacol 10: 327
Juma FD, Koech DK, Kasili EG, Ogada T (1984) Pharmacokinetics of cyclophosphamide in Kenyan African children with lymphoma. Br J Clin Pharmacol 18: 106
Manthey CL, Sladek NE (1988) Kinetic characterization of the catalysis of “activated” cyclophosphamide (4-hydroxycyclophosphamide/aldophosphamide) oxidation to carboxyphosphamide by mouse hepatic aldehyde dehydrogenases. Biochem Pharmacol 37: 2781
Moore MJ (1991) Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 20: 194
Sladek NE (1988) Metabolism of oxazaphosphorines. Pharmacol Ther 37: 301
Sladek NE, Priest J, Doeden D, Mirocha CJ, Pathre S, Krivit W (1980) Plasma half-life and urinary excretion of cyclophosphamide in children. Cancer Treat Rep 64: 1061
Tchekmedyian NS, Egorin MJ, Brian EC, Kaplan RS, Poplin E (1986) Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusion. Cancer Chemother Pharmacol 18: 33
Author information
Authors and Affiliations
Additional information
M.J.T. was supported by a grant from the Fondo de Investigacion Sanitaria, Ministerio de Sanidad y Consumo, Spain. This work was also supported in part by grants from the North of England Cancer Research Campaign, North of England Children's Cancer Research Fund, ASTA Werke Germany, and the Wellcome Trust.
Rights and permissions
About this article
Cite this article
Tasso, M.J., Boddy, A.V., Price, L. et al. Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients. Cancer Chemother. Pharmacol. 30, 207–211 (1992). https://doi.org/10.1007/BF00686313
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686313